Limits...
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C - Cancer Biother. Radiopharm. (2015)

Bottom Line: Treatment with DC-TC was associated with longer OS in both cohorts.Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025).This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

View Article: PubMed Central - PubMed

Affiliation: 1 Caladrius Biosciences, Inc. , Irvine, California.

ABSTRACT
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous tumor cells (DC-TC) showed superior survival compared with similar patients immunized with irradiated tumor cells (TC). We wished to determine whether this difference was evident in cohorts who at the time of treatment had (1) no evidence of disease (NED) or (2) had detectable disease. Eligibility criteria and treatment schedules were the same for all three trials. Pooled data confirmed that overall survival (OS) was longer in 72 patients treated with DC-TC compared with 71 patients treated with TC (median OS 60 versus 22 months; 5-year OS 51% versus 32%, p=0.004). Treatment with DC-TC was associated with longer OS in both cohorts. Among 70 patients who were NED at the time that treatment was started, OS was better for DC-TC: 5-year OS 73% versus 43% (p=0.015). Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025). This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

No MeSH data available.


Related in: MedlinePlus

Survival curves for patients who had detectable metastatic melanoma at the start of ASI by treatment product: DC-TC (n=39) versus TC (n=34), HR=0.66, p=0.025.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4492594&req=5

f5: Survival curves for patients who had detectable metastatic melanoma at the start of ASI by treatment product: DC-TC (n=39) versus TC (n=34), HR=0.66, p=0.025.

Mentions: The DC-TC versus TC comparison for the NED subset of patients is shown in Figure 4, and for the non-NED subset in Figure 5. Median follow up was more than 5 years for all cohorts, and no patients were lost to follow up. For the 70 patients who were NED when ASI was initiated, survival was better for those who received DC-TC with median OS not reached versus 32.2 months and 5-year survival rates of 73% versus 43% (p=0.015, HR=0.39). In the subset of non-NED patients enrolled in the randomized trial, there was a similar benefit for 8 patients treated with DC-TC compared with 11 treated with TC (p=0.005). For the 73 patients who were not NED at the start of treatment, that is, they had measurable disease or detectable disease that was considered non-measurable or equivocal, survival was also better for those who received DC-TC with median survival of 38.8 months versus 14.7 months and 5-year OS 33% versus 20% (p=0.025, HR=0.66). In the subset of NED patients enrolled in trial #3, limited data showed a similar benefit for 10 patients treated with DC-TC compared with 13 treated with TC (p=0.11).


Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C - Cancer Biother. Radiopharm. (2015)

Survival curves for patients who had detectable metastatic melanoma at the start of ASI by treatment product: DC-TC (n=39) versus TC (n=34), HR=0.66, p=0.025.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4492594&req=5

f5: Survival curves for patients who had detectable metastatic melanoma at the start of ASI by treatment product: DC-TC (n=39) versus TC (n=34), HR=0.66, p=0.025.
Mentions: The DC-TC versus TC comparison for the NED subset of patients is shown in Figure 4, and for the non-NED subset in Figure 5. Median follow up was more than 5 years for all cohorts, and no patients were lost to follow up. For the 70 patients who were NED when ASI was initiated, survival was better for those who received DC-TC with median OS not reached versus 32.2 months and 5-year survival rates of 73% versus 43% (p=0.015, HR=0.39). In the subset of non-NED patients enrolled in the randomized trial, there was a similar benefit for 8 patients treated with DC-TC compared with 11 treated with TC (p=0.005). For the 73 patients who were not NED at the start of treatment, that is, they had measurable disease or detectable disease that was considered non-measurable or equivocal, survival was also better for those who received DC-TC with median survival of 38.8 months versus 14.7 months and 5-year OS 33% versus 20% (p=0.025, HR=0.66). In the subset of NED patients enrolled in trial #3, limited data showed a similar benefit for 10 patients treated with DC-TC compared with 13 treated with TC (p=0.11).

Bottom Line: Treatment with DC-TC was associated with longer OS in both cohorts.Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025).This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

View Article: PubMed Central - PubMed

Affiliation: 1 Caladrius Biosciences, Inc. , Irvine, California.

ABSTRACT
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous tumor cells (DC-TC) showed superior survival compared with similar patients immunized with irradiated tumor cells (TC). We wished to determine whether this difference was evident in cohorts who at the time of treatment had (1) no evidence of disease (NED) or (2) had detectable disease. Eligibility criteria and treatment schedules were the same for all three trials. Pooled data confirmed that overall survival (OS) was longer in 72 patients treated with DC-TC compared with 71 patients treated with TC (median OS 60 versus 22 months; 5-year OS 51% versus 32%, p=0.004). Treatment with DC-TC was associated with longer OS in both cohorts. Among 70 patients who were NED at the time that treatment was started, OS was better for DC-TC: 5-year OS 73% versus 43% (p=0.015). Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025). This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

No MeSH data available.


Related in: MedlinePlus